This page contains a Flash digital edition of a book.
For eff ective relief


from the symptoms of allergy and hayfever1,2


• Eff ective and fast-acting1,2 • Once daily in adults • Easy–to–take tablets • Available in pack sizes of 7, 14 and 30 tablets


Order now: Pack Size RRP*(£)


(Cetirizine hydrochloride 10mg tablets) Allergy relief for all seasons


Allacan 7s Allacan 14s Allacan 30s


£2.00 £3.00 £4.00


Listed Trade Price (£)


£1.50 £2.25 £3.00


PIP Code


388-5803 388-4376 388-5811


EAN Code


506001394 2990 506001394 4468 506001394 4598


PRESCRIBING INFORMATION Product name: Allacan (Cetirizine hydrochloride 10mg tablets) Indications: Patients 6 years and above: Relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis, relief of chronic idiopathic urticaria. Posology and method of administration: Tablets to be swallowed with water. Patients aged 6 to 12 years: - 5mg twice daily (half tablet twice daily). Patients 12 years and above: - 10mg once daily (one tablet). Patients with moderate to severe renal impairment: - Dosage adjustment to be individualised in line with renal function – See Summary of Product Characteristics (SmPC), Patients with hepatic and renal impairment: Dosage adjustment is recommended – See SmPC. Contraindications: Known hypersensitivity to cetirizine or any of the excipients; severe renal impairment, galactose intolerance, lapp- lactase defi ciency and glucose-galactose malabsorption. Special warnings: Use with caution in breastfeeding and epileptic patients. Undesirable eff ects: somnolence, fatigue, dizziness, headache dry mouth, eye accommodation, isolated elevation of hepatic enzymes. Product Licence Holder: Bristol Laboratories Limited, Unit 3, Canalside, Northbridge Road, Berkhamsted, Hertfordshire, HP4 1EG (PL 17907/ 0046) Date of Authorisation: 07/09/2004 Recommended Price: 7 Tablets £2.00, 14 Tablets £3.00, 30 Tablets £4.00. Date of Prescribing Information: 27/02/2015 GSL


Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows monitoring of the benefi t/risk balance of the medicinal product. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.


Adverse events should also be reported to Bristol Laboratories Medical Information Department on Telephone: 0044 (0) 1442 200 922


References: 1. Allacan SmPC - Jan 2015 2. Zhang L et al. The Clinical Use of Cetirizine in the Treatment of Allergic Rhinitis, Pharmacology 2013; 92:14-25.


*Recommended Retail Price Date of preparation: March 2015 Code: UK/ALL/ADV10ga/03/2015


Quality • Consistency • Excellence www.bristol-labs.co.uk


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60